Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 45, 3548-3553, August 1, 1985]
© 1985 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kataoka, T.
Right arrow Articles by Suhara, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kataoka, T.
Right arrow Articles by Suhara, Y.

Treatment Regimen and Host T-Cell-dependent Therapeutic Effect of Interferon in Mouse Solid Tumors1

Tateshi Kataoka2, Naomi Matsuura, Fujiko Oh-hashi and Yasuji Suhara

Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research [T. K., F. O.], 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo 170 and Department of Microbiology and Chemotherapy, Nippon Roche Research Center, Kamakura 247, Japan [N. M., Y. S.]

A highly purified hybrid human interferon (IFN)-{alpha} A/D, was used to define optimum treatment regimens for Meth A fibrosarcoma intradermally inoculated in syngeneic BALB/c mice. Treatments from the sixth day post-tumor inoculation were most effective, and 10 consecutive injections of IFN completely suppressed the tumor growth for a prolonged time without recurrence after the last injection of IFN. Intraperitoneal and intravenous injections were similarly effective.

The therapeutic effect of IFN was abrogated by the injection of rabbit {alpha}-mouse thymocyte globulin but not normal rabbit globulin. The therapeutic effect of IFN was much poorer in BALB/c nu/nu mice, which are athymic and defective in T-cell immunity, than in BALB/c +/+ mice. Mice in which Meth A growth was completely suppressed by IFN were refractory to Meth A, but not Meth 1 tumor, another antigenically distinct fibrosarcoma, whereas mice in which Meth 1 growth was suppressed completely by IFN were refractory to Meth 1 but not Meth A tumor. These three findings suggest that the therapeutic effect of IFN depended on host T-cell immunity and that tumors were eventually eliminated by tumor-selective antitumor immunity provoked during IFN therapy. Under the present experimental conditions, the direct anticellular activity of IFN was presumed to contribute very little to the therapy for solid tumors, since the therapeutic effect of IFN on three different solid tumors was not correlated with their in vitro sensitivity to this substance: Colon 26, which was as sensitive to IFN as Meth A in the in vitro antiproliferation, responded most poorly to IFN therapy, while Meth A and Meth 1 responded similarly well to IFN therapy, although there was more than a 2500 times difference in their in vitro IFN sensitivity.

1 This research was supported in part by a Grant-in-Aid from the Ministry of Health and Welfare and the Ministry of Education, Science, and Culture, a Grant-in-Aid for the New Drug Development Research from the Ministry of Health and Welfare, Japan, and the Foundation for Promotion of Cancer Research [T. K.]. This is the fourth in a series of papers on antineoplastic cytokines.

2 To whom requests for reprints should be addressed.

Received 10/18/84. Revised 4/24/85. Accepted 4/24/85.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1985 by the American Association for Cancer Research.